Galectin Therapeutics Inc.
GALT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $37 | $33 | $32 | $41 |
| Gross Profit | -$37 | -$33 | -$32 | -$41 |
| % Margin | – | – | – | – |
| R&D Expenses | $36,571 | $32,130 | $31,737 | $23,818 |
| G&A Expenses | $0 | $5,898 | $0 | $0 |
| SG&A Expenses | $5,825 | $5,942 | $6,583 | $6,320 |
| Sales & Mktg Exp. | $0 | $44 | $0 | $0 |
| Other Operating Expenses | $0 | -$0 | $0 | $0 |
| Operating Expenses | $42,396 | $38,039 | $38,320 | $30,138 |
| Operating Income | -$42,433 | -$38,072 | -$38,352 | -$30,179 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$4,614 | -$2,994 | -$424 | -$348 |
| Pre-Tax Income | -$47,047 | -$41,066 | -$38,776 | -$30,527 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$47,047 | -$41,066 | -$38,776 | -$30,527 |
| % Margin | – | – | – | – |
| EPS | -0.76 | -0.74 | -0.65 | -0.52 |
| % Growth | -2.7% | -13.8% | -25% | – |
| EPS Diluted | -0.76 | -0.74 | -0.65 | -0.52 |
| Weighted Avg Shares Out | 62,309 | 60,159 | 59,391 | 58,527 |
| Weighted Avg Shares Out Dil | 62,309 | 60,159 | 59,391 | 58,527 |
| Supplemental Information | – | – | – | – |
| Interest Income | $338 | $230 | $52 | $3 |
| Interest Expense | $5,540 | $2,792 | $1,033 | $489 |
| Depreciation & Amortization | $37 | $33 | $32 | $41 |
| EBITDA | -$41,470 | -$38,241 | -$37,711 | -$29,997 |
| % Margin | – | – | – | – |